Compare BRBS & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBS | TLSI |
|---|---|---|
| Founded | 1893 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.8M | 270.2M |
| IPO Year | 2015 | N/A |
| Metric | BRBS | TLSI |
|---|---|---|
| Price | $3.46 | $4.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 363.4K | ★ 387.1K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 24.78% | N/A |
| EPS Growth | ★ 135.48 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $111,284,000.00 | N/A |
| Revenue This Year | N/A | $35.45 |
| Revenue Next Year | N/A | $37.58 |
| P/E Ratio | $339.00 | ★ N/A |
| Revenue Growth | ★ 123.99 | N/A |
| 52 Week Low | $3.23 | $2.20 |
| 52 Week High | $4.79 | $7.95 |
| Indicator | BRBS | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 53.11 |
| Support Level | $3.41 | $3.69 |
| Resistance Level | $3.53 | $4.39 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 56.25 | 81.08 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance, and others. It generates the majority of its revenue from commercial banking.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.